The Global Fund Board has recently approved several multicountry grants, whose aim is to address priorities “deemed critical to fulfil the aims of the Global Fund 2017-2022 strategy,” and to address needs that are not being fulfilled by national (single country) allocations.
You are here
Global Fund’s new HIV and TB multicountry grants in Eastern Europe and Central Asia begin implementation
Le Conseil d’administration du Fonds mondial approuve une nouvelle tranche de 98 millions de dollars de subventions des allocations 2017/2019
Of the $98 million in country grants approved by Global Fund Board from 2017-2019 allocations, Latin America and Caribbean receive $57 million
This is the second of two articles in this issue on the grants recently approved by the Global Fund Board. In this article, we report on the comments of the Grant Approvals Committee (GAC) on four countries in the Latin American and Caribbean region: Belize, El Salvador, Panama and Paraguay.
On 12 November 2018, through electronic voting, the Global Fund Board approved $98.0 million in funding for 14 country grants from 13 countries. Of the 14 grants, four were for TB; three TB/HIV; three HIV; three malaria; and one TB/RSSH.
Global Fund grant to Belarus in 2015 was conditional on the government developing a social contracting mechanism
A social contracting mechanism which would allow the government to contract with NGOs to deliver prevention programs to key affected populations in Belarus is “under construction.” It is a slow process and there are still some uncertainties about how well it will function.
A comparative study of opioid substitution therapy protocols will contribute to the sustainability of harm reduction in the Eastern Europe and Central Asia region
The new methodology for the funding allocations and consequent gradual decrease of GF financing for the Eastern Europe and Central Asia (EECA) countries puts at special risk the operations of harm reduction services, which were, traditionally, largely supported by the GF.